{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:08:03Z","timestamp":1795018083737,"version":"4.10.1"},"reference-count":172,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPR"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Vitiligo is a relatively common acquired pigmentation disorder that can\ncause significant psychological stress and stigmatism.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This article aims to familiarize physicians with the clinical manifestations, evaluation,\ndiagnosis, and management of vitiligo.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A Pubmed search was conducted in Clinical Queries using the key term \u201cvitiligo\u201d. The\nsearch included meta-analyses, randomized controlled trials, clinical trials, observational studies,\nand reviews. The search was restricted to English language. The information retrieved from the\nabove search was used in the compilation of the present article.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Approximately one quarter of patients with vitiligo have the onset before 10 years of age.\nGenetic, immunological, neurogenic and environmental factors may have a role to play in the\npathogenesis. Vitiligo typically presents as acquired depigmented, well-demarcated macules\/patches\nthat appear milk- or chalk-white in color. Lesions tend to increase in number and enlarge centrifugally\nin size with time. Sites of predilection include the face, followed by the neck, lower\nlimbs, trunk, and upper limbs. The clinical course is generally unpredictable. In children with fair\nskin, no active treatment is usually necessary other than the use of sunscreens and camouflage cosmetics.\nIf treatment is preferred for cosmesis, topical corticosteroids, topical calcineurin inhibitors,\nand narrowband ultraviolet B phototherapy are the mainstays of treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The therapeutic effect of all the treatment modalities varies considerably from individual\nto individual. As such, treatment must be individualized. In general, the best treatment response\nis seen in younger patients, recent disease onset, darker skin types, and head and neck lesions. Topical\ncorticosteroids and calcineurin inhibitors are the treatment choice for those with localized disease.\nTopical calcineurin inhibitors are generally preferred for lesions on genitalia, intertriginous areas,\nface, and neck. Narrowband ultraviolet B phototherapy should be considered in patients who\nhave widespread vitiligo or those with localized vitiligo associated with a significant impact on the\nquality of life who do not respond to treatment with topical corticosteroids and calcineurin inhibitors.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573396316666201210125858","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T04:11:37Z","timestamp":1607659897000},"page":"76-91","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Vitiligo: An Updated Narrative Review"],"prefix":"10.2174","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-6971","authenticated-orcid":true,"given":"Alexander K.C.","family":"Leung","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The University of Calgary, The Alberta Children\u2019s Hospital, Calgary, Alberta,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-3369","authenticated-orcid":true,"given":"Joseph M.","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Department of Dermatology and Skin Sciences, University of British Columbia, Vancouver, British Columbia,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-7960","authenticated-orcid":true,"given":"Kin Fon","family":"Leong","sequence":"additional","affiliation":[{"name":"Pediatric Institute, Kuala Lumpur General Hospital, Kuala Lumpur,Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6682-5529","authenticated-orcid":true,"given":"Kam Lun","family":"Hon","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, The Chinese University of Hong Kong, and Department of Paediatrics and Adolescent Medicine, The Hong Kong Children\u2019s Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1529-8019.2008.00178.x","volume":"21","author":"Lotti T.","year":"2008","unstructured":"Lotti T.; Gori A.; Zanieri F.; Colucci R.; Moretti S.; Vitiligo: new and emerging treatments. Dermatol Ther 2008,21(2),110-117","journal-title":"Dermatol Ther"},{"key":"ref=2","first-page":"103","volume":"1","author":"Leung A.K.C.","year":"2013","unstructured":"Leung A.K.C.; Barankin B.; Hon K.L.; Vitiligo. Pediatr Neon Care 2013,1,103","journal-title":"Pediatr Neon Care"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"CD003263","DOI":"10.1002\/14651858.CD003263.pub5","author":"Whitton M.E.","year":"2015","unstructured":"Whitton M.E.; Pinart M.; Batchelor J.; Leonardi-Bee J.; Gonz&#xE1;lez U.; Jiyad Z.; Eleftheriadou V.; Ezzedine K.; Interventions for vitiligo. Cochrane Database Syst Rev 2015(2),CD003263","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/pde.13431","volume":"35","author":"Tay E.Y.","year":"2018","unstructured":"Tay E.Y.; Chong C.L.V.; Chong W.J.J.P.; Gan Y.E.; Chuah S.Y.; Tan W.D.V.; Thng T.G.S.; Treatment outcomes of vitiligo in Asian children. Pediatr Dermatol 2018,35(2),265-267","journal-title":"Pediatr Dermatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000506103","author":"Bergqvist C","year":"2020","unstructured":"Bergqvist C; Ezzedine K.; Vitiligo: A review. Dermatology 2020,1-2","journal-title":"Dermatology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/pcmr.12681","volume":"31","author":"Cesar Silva de Castro C.","year":"2018","unstructured":"Cesar Silva de Castro C.; Miot H.A.; Prevalence of vitiligo in Brazil-A population survey. Pigment Cell Melanoma Res 2018,31(3),448-450","journal-title":"Pigment Cell Melanoma Res"},{"key":"ref=7","first-page":"1717","volume":"2018","author":"Matin R.","year":"2008","unstructured":"Matin R.; Vitiligo in adults and children. Clin Evid 2008,2018,1717","journal-title":"Clin Evid"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMcp0804388","volume":"360","author":"Ta&#xEF;eb A.","year":"2009","unstructured":"Ta&#xEF;eb A.; Picardo M.; Clinical practice. Vitiligo. N Engl J Med 2009,360(2),160-169","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e0163806","DOI":"10.1371\/journal.pone.0163806","volume":"11","author":"Zhang Y.","year":"2016","unstructured":"Zhang Y.; Cai Y.; Shi M.; Jiang S.; Cui S.; Wu Y.; Gao X.H.; Chen H.D.; The prevalence of vitiligo: A meta-analysis. PLoS One 2016,11(9),e0163806","journal-title":"PLoS One"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.4081\/pr.2017.7300","volume":"9","author":"Barro M.","year":"2017","unstructured":"Barro M.; Diallo J.W.; Ouattara A.B.I.; Nacro B.; Congenital vitiligo: A case observed in the cohort of HIV-exposed infants in Bobo-Dioulasso, Burkina Faso. Pediatr Rep 2017,9(3),7300","journal-title":"Pediatr Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/1203475416629132","volume":"20","author":"Kambhampati B.N.","year":"2016","unstructured":"Kambhampati B.N.; Sawatkar G.U.; Kumaran M.S.; Parsad D.; Congenital vitiligo: A case report. J Cutan Med Surg 2016,20(4),354-355","journal-title":"J Cutan Med Surg"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1346-8138.2010.01139.x","volume":"38","author":"Yaghoobi R.","year":"2011","unstructured":"Yaghoobi R.; Omidian M.; Bagherani N.; Vitiligo: a review of the published work. J Dermatol 2011,38(5),419-431","journal-title":"J Dermatol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","volume":"168","author":"Taieb A.","year":"2013","unstructured":"Taieb A.; Alomar, B&#xF6;hm M.; Dell'anna ML.; De Pase A.; Eleftheriadou V.; Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 2013,168,5-19","journal-title":"Br J Dermatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","volume":"65","author":"Alikhan A.","year":"2011","unstructured":"Alikhan A.; Felsten L.M.; Daly M.; Petronic-Rosic V.; Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011,65(3),473-491","journal-title":"J Am Acad Dermatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clindermatol.2017.01.001","volume":"35","author":"Cupertino F.","year":"2017","unstructured":"Cupertino F.; Niemeyer-Corbellini J.P.; Ramos-E-Silva M.; Psychosomatic aspects of vitiligo. Clin Dermatol 2017,35(3),292-297","journal-title":"Clin Dermatol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.sder.2009.04.008","volume":"28","author":"Halder R.M.","year":"2009","unstructured":"Halder R.M.; Chappell J.L.; Vitiligo update. Semin Cutan Med Surg 2009,28(2),86-92","journal-title":"Semin Cutan Med Surg"},{"key":"ref=17","author":"Grimes PE","unstructured":"Grimes PE; Vitiligo: Pathogenesis, clinical features, and diagnosis. UpToDate","journal-title":"UpToDate"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","volume":"38","author":"Frisoli M.L.","year":"2020","unstructured":"Frisoli M.L.; Essien K.; Harris J.E.; Vitiligo: Mechanisms of pathogenesis and treatment. Annu Rev Immunol 2020,38,621-648","journal-title":"Annu Rev Immunol"},{"key":"ref=19","first-page":"277","volume":"79","author":"Huggins R.H.","year":"2007","unstructured":"Huggins R.H.; Schwartz R.A.; Janniger C.K.; Childhood vitiligo. Cutis 2007,79(4),277-280","journal-title":"Cutis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","volume":"18","author":"Speeckaert R.","year":"2017","unstructured":"Speeckaert R.; van Geel N.; Vitiligo: An update on pathophysiology and treatment options. Am J Clin Dermatol 2017,18(6),733-744","journal-title":"Am J Clin Dermatol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3889\/oamjms.2018.040","volume":"6","author":"Gianfaldoni S.","year":"2018","unstructured":"Gianfaldoni S.; Tchernev G.; Wollina U.; Lotti J.; Satolli F.; Fran&#xE7;a K.; Rovesti M.; Lotti T.; Vitiligo in children: A better understanding of the disease. Open Access Maced J Med Sci 2018,6(1),181-184","journal-title":"Open Access Maced J Med Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5412806","DOI":"10.1155\/2016\/5412806","volume":"2016","author":"Li Z.","year":"2016","unstructured":"Li Z.; Ren J.; Niu X.; Xu Q.; Wang X.; Liu Y.; Xiao S.; Meta-analysis of the association between vitiligo and human leukocyte antigen-A. BioMed Res Int 2016,2016,5412806","journal-title":"BioMed Res Int"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e8046","DOI":"10.7759\/cureus.8046","volume":"12","author":"Almohideb M.","year":"2020","unstructured":"Almohideb M.; Associations of angiotensin-converting enzyme gene insertion\/deletion (ACE gene I\/D) polymorphism with vitiligo: An updated systematic review and meta-analysis. Cureus 2020,12(5),e8046","journal-title":"Cureus"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.4049\/jimmunol.0713370","volume":"182","author":"Arechiga A.F.","year":"2009","unstructured":"Arechiga A.F.; Habib T.; He Y.; Zhang X.; Zhang Z.Y.; Funk A.; Buckner J.H.; Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 2009,182(6),3343-3347","journal-title":"J Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/ijd.IJD_104_18","volume":"65","author":"Bakry O.","year":"2020","unstructured":"Bakry O.; Mariee A.; Badr I.; Tayel N.; El Gendy S.; NPY gene polymorphism in vitiligo: A case-control study in Egyptian patients. Indian J Dermatol 2020,65(1),65-67","journal-title":"Indian J Dermatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/exd.14100","volume":"29","author":"Martins L.T.","year":"2020","unstructured":"Martins L.T.; Frigeri H.R.; de Castro C.C.S.; Mira M.T.; Association study between vitiligo and autoimmune-related genes CYP27B1, REL, TNFAIP3, IL2 and IL21. Exp Dermatol 2020,29(6),535-538","journal-title":"Exp Dermatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/MOP.0b013e32833b6ac3","volume":"22","author":"Silverberg N.B.","year":"2010","unstructured":"Silverberg N.B.; Update on childhood vitiligo. Curr Opin Pediatr 2010,22(4),445-452","journal-title":"Curr Opin Pediatr"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/ijd.IJD_388_18","volume":"65","author":"Srivastava D.S.L.","year":"2020","unstructured":"Srivastava D.S.L.; Aggarwal K.; Singh G.; Is NAT2 gene polymorphism associated with vitiligo? Indian J Dermatol 2020,65(3),173-177","journal-title":"Indian J Dermatol"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13025","volume":"32","author":"Yuan X","year":"2019","unstructured":"Yuan X; Meng D; Cao P; Sun L; Pang Y; Li Y; Identification of pathogenic genes and transcription factors in vitiligo. Dermatol Ther 2019,32(5)","journal-title":"Dermatol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jaad.2019.06.022","volume":"81","author":"Chang H.C.","year":"2019","unstructured":"Chang H.C.; Lin M.H.; Huang Y.C.; Hou T.Y.; The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis. J Am Acad Dermatol 2019,81(6),1442-1445","journal-title":"J Am Acad Dermatol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/ijd.14055","volume":"57","author":"Dahir A.M.","year":"2018","unstructured":"Dahir A.M.; Thomsen S.F.; Comorbidities in vitiligo: comprehensive review. Int J Dermatol 2018,57(10),1157-1164","journal-title":"Int J Dermatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaad.2019.07.036","volume":"82","author":"Hadi A.","year":"2020","unstructured":"Hadi A.; Wang J.F.; Uppal P.; Penn L.A.; Elbuluk N.; Comorbid diseases of vitiligo: A 10-year cross-sectional retrospective study of an urban US population. J Am Acad Dermatol 2020,82(3),628-633","journal-title":"J Am Acad Dermatol"},{"key":"ref=33","first-page":"pp. 229","volume":"Vol. 2","author":"Leung A.K.C.","year":"2011","unstructured":"Leung A.K.C.;  Common Problems in Ambulatory Pediatrics: Specific Clinical Problems  New York Nova Science Publishers, Inc 2011,Vol. 2,pp. 229-34","journal-title":"Common Problems in Ambulatory Pediatrics: Specific Clinical Problems  New York Nova Science Publishers, Inc"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/120347541201600408","volume":"16","author":"Sawicki J.","year":"2012","unstructured":"Sawicki J.; Siddha S.; Rosen C.; Vitiligo and associated autoimmune disease: retrospective review of 300 patients. J Cutan Med Surg 2012,16(4),261-266","journal-title":"J Cutan Med Surg"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/j.1365-2133.2012.11198.x","volume":"167","author":"Vrijman C.","year":"2012","unstructured":"Vrijman C.; Kroon M.W.; Limpens J.; Leeflang M.M.G.; Luiten R.M.; van der Veen J.P.; Wolkerstorfer A.; Spuls P.I.; The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol 2012,167(6),1224-1235","journal-title":"Br J Dermatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","volume":"35","author":"Spritz R.A.","year":"2017","unstructured":"Spritz R.A.; Andersen G.H.; Genetics of Vitiligo. Dermatol Clin 2017,35(2),245-255","journal-title":"Dermatol Clin"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.autrev.2015.12.006","volume":"15","author":"Iannella G.","year":"2016","unstructured":"Iannella G.; Greco A.; Didona D.; Didona B.; Granata G.; Manno A.; Pasquariello B.; Magliulo G.; Vitiligo: Pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 2016,15(4),335-343","journal-title":"Autoimmun Rev"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/ijms21103552","volume":"21","author":"Fr\u0105czek A.","year":"2020","unstructured":"Fr\u0105czek A.; Owczarczyk-Saczonek A.; Placek W.; The role of T cells in the pathogenesis of vitiligo - A review of the current state-of-the-art. Int J Mol Sci 2020,21(10),3552","journal-title":"Int J Mol Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1111\/ajd.13233","volume":"61","author":"Acharya P.","year":"2020","unstructured":"Acharya P.; Mathur M.; Interleukin-17 level in patients with vitiligo: A systematic review and meta-analysis. Australas J Dermatol 2020,61(2),e208-e212","journal-title":"Australas J Dermatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1111\/jdv.15016","volume":"32","author":"Gomes I.A.","year":"2018","unstructured":"Gomes I.A.; de Carvalho F.O.; de Menezes A.F.; Almeida F.M.; Shanmugam S.; de Souza Siqueira Quintans J.; Quintans-J&#xFA;nior L.J.; de Moura T.R.; Oliveira P.D.; de Souza Ara&#xFA;jo A.A.; The role of interleukins in vitiligo: a systematic review. J Eur Acad Dermatol Venereol 2018,32(12),2097-2111","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"88179","DOI":"10.18632\/oncotarget.21165","volume":"8","author":"Li J.","year":"2017","unstructured":"Li J.; Yan M.; Zhang Y.; Feng C.; Wang H.; Wang C.; Sun L.; Meta-analysis of the association between NLRP1 polymorphisms and the susceptibility to vitiligo and associated autoimmune diseases. Oncotarget 2017,8(50),88179-88188","journal-title":"Oncotarget"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e20154126","DOI":"10.1542\/peds.2015-4126","volume":"138","author":"Ezzedine K.","year":"2016","unstructured":"Ezzedine K.; Silverberg N.; A practical approach to the diagnosis and treatment of vitiligo in children. Pediatrics 2016,138(1),e20154126","journal-title":"Pediatrics"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.clindermatol.2013.11.011","volume":"32","author":"Lotti T.","year":"2014","unstructured":"Lotti T.; D\u2019Erme A.M.; Vitiligo as a systemic disease. Clin Dermatol 2014,32(3),430-434","journal-title":"Clin Dermatol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","volume":"151","author":"Mohan G.C.","year":"2015","unstructured":"Mohan G.C.; Silverberg J.I.; Association of vitiligo and alopecia areata with atopic dermatitis: A systematic review and meta-analysis. JAMA Dermatol 2015,151(5),522-528","journal-title":"JAMA Dermatol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.pcl.2013.11.008","volume":"61","author":"Silverberg N.B.","year":"2014","unstructured":"Silverberg N.B.; Pediatric vitiligo. Pediatr Clin North Am 2014,61(2),347-366","journal-title":"Pediatr Clin North Am"},{"key":"ref=46","author":"Acharya P","year":"2019","unstructured":"Acharya P; Mathur M; Association of atopic dermatitis with vitiligo: A systematic review and meta-analysis. J Cosmet Dermatol 2019","journal-title":"J Cosmet Dermatol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0394-1","volume":"20","author":"Yen H.","year":"2019","unstructured":"Yen H.; Chi C.C.; Association between psoriasis and vitiligo: A systematic review and meta-analysis. Am J Clin Dermatol 2019,20(1),31-40","journal-title":"Am J Clin Dermatol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","volume":"35","author":"Rashighi M.","year":"2017","unstructured":"Rashighi M.; Harris J.E.; Vitiligo pathogenesis and emerging treatments. Dermatol Clin 2017,35(2),257-265","journal-title":"Dermatol Clin"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1179\/1351000212Y.0000000025","volume":"17","author":"Yesilova Y.","year":"2012","unstructured":"Yesilova Y.; Turan E.; Ucmak D.; Selek S.; Halil Yavuz \u0130.; Tanr\u0131kulu O.; Reduced serum paraoxonase-1 levels in vitiligo: further evidence of oxidative stress. Redox Rep 2012,17(5),214-218","journal-title":"Redox Rep"},{"key":"ref=50","author":"Mathachan SR","year":"2020","unstructured":"Mathachan SR; Khurana A; Gautam RK; Kulhari A; Sharma L; Sardana K; Does oxidative stress correlate with disease activity and severity in vitiligo? An analytical study. J Cosmet Dermatol 2020","journal-title":"J Cosmet Dermatol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/ijd.IJD_457_16","volume":"63","author":"Mirnezami M.","year":"2018","unstructured":"Mirnezami M.; Rahimi H.; Serum zinc level in vitiligo: A case-control study. Indian J Dermatol 2018,63(3),227-230","journal-title":"Indian J Dermatol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"126570","DOI":"10.1016\/j.jtemb.2020.126570","volume":"12","author":"Huo J","year":"2020","unstructured":"Huo J; Liu T; Huan Y; Li F; Wang R; Serum level of antioxidant vitamins and minerals in patients with vitiligo, a systematic review and meta-analysis. J Trace Elem Med Biol 2020,12,126570","journal-title":"J Trace Elem Med Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"E968","DOI":"10.1503\/cmaj.190070","volume":"191","author":"Liu W","year":"2019","unstructured":"Liu W; Ma DL; Koebner phenomenon in vitiligo after suction blister epidermal grafting. CMAJ 2019,191(35),E968","journal-title":"CMAJ"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1365-2133.2012.11111.x","volume":"167","author":"van Geel N.","year":"2012","unstructured":"van Geel N.; Speeckaert R.; De Wolf J.; Bracke S.; Chevolet I.; Brochez L.; Lambert J.; Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol 2012,167(5),1017-1024","journal-title":"Br J Dermatol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"302","DOI":"10.5021\/ad.2017.29.3.302","volume":"29","author":"Khurrum H.","year":"2017","unstructured":"Khurrum H.; AlGhamdi K.M.; Bedaiwi K.M.; AlBalahi N.M.; Multivariate analysis of factors associated with the Koebner phenomenon in vitiligo: An observational study of 381 patients. Ann Dermatol 2017,29(3),302-306","journal-title":"Ann Dermatol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/fcp.12558","volume":"34","author":"Anthony N","year":"2020","unstructured":"Anthony N; Bourneau-Martin D; Ghamrawi S; Lagarce L; Babin M; Briet M.; Drug-induced vitiligo: a case\/non-case study in Vigibase(&#xAE;), the WHO pharmacovigilance database. Fundam Clin Pharmacol 2020,34(6),736-42","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e12351","DOI":"10.1111\/appy.12351","volume":"11","author":"Guler Aksu G.","year":"2019","unstructured":"Guler Aksu G.; Akdere P.; Toros F.; Methylphenidate associated vitiligo in a child: A case report. Asia-Pac Psychiatry 2019,11(3),e12351","journal-title":"Asia-Pac Psychiatry"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3697260","DOI":"10.1155\/2018\/3697260","volume":"2018","author":"Kokandi A.A.","year":"2018","unstructured":"Kokandi A.A.; Vitiligo appearing after oral isotretinoin therapy for acne. Case Rep Dermatol Med 2018,2018,3697260","journal-title":"Case Rep Dermatol Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"E481","DOI":"10.21037\/jtd.2018.05.104","volume":"10","author":"Nishino K.","year":"2018","unstructured":"Nishino K.; Ohe S.; Kitamura M.; Kunimasa K.; Kimura M.; Inoue T.; Tamiya M.; Kumagai T.; Nakatsuka S.I.; Isei T.; Imamura F.; Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung. J Thorac Dis 2018,10(6),E481-E484","journal-title":"J Thorac Dis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"637","DOI":"10.36849\/JDD.2020.4938","volume":"19","author":"O\u2019Connor M.","year":"2020","unstructured":"O\u2019Connor M.; Silverberg J.I.; Silverberg N.B.; The effect of isotretinoin on vitiligo and autoimmune comorbidity. J Drugs Dermatol 2020,19(6),637-638","journal-title":"J Drugs Dermatol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"e13007","DOI":"10.1111\/dth.13007","volume":"32","author":"Turkowski Y.","year":"2019","unstructured":"Turkowski Y.; Konnikov N.; Sulfasalazine-induced generalized vitiligo in a patient with dermatitis herpetiformis and celiac disease. Dermatol Ther (Heidelb) 2019,32(5),e13007","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"581657","DOI":"10.1155\/2014\/581657","volume":"2014","author":"Khalil A.","year":"2014","unstructured":"Khalil A.; Zaidman I.; Bergman R.; Elhasid R.; Ben-Arush M.W.; Autoimmune complications after hematopoietic stem cell transplantation in children with nonmalignant disorders. ScientificWorldJournal 2014,2014,581657","journal-title":"ScientificWorldJournal"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/1471-2334-14-329","volume":"14","author":"Li W.","year":"2014","unstructured":"Li W.; Xin H.; Ge L.; Song H.; Cao W.; Induction of vitiligo after imiquimod treatment of condylomata acuminata. BMC Infect Dis 2014,14,329","journal-title":"BMC Infect Dis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/ced.12921","volume":"41","author":"Mori S.","year":"2016","unstructured":"Mori S.; Akasaka T.; Imiquimod-induced vitiligo-like hypopigmentation after treatment for radiation keratosis. Clin Exp Dermatol 2016,41(8),930-932","journal-title":"Clin Exp Dermatol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jdcr.2019.03.015","volume":"5","author":"Tkachenko E.","year":"2019","unstructured":"Tkachenko E.; Lin J.Y.; Hartman R.I.; Regional vitiligo induced by imiquimod treatment for in-transit melanoma metastases. JAAD Case Rep 2019,5(5),427-429","journal-title":"JAAD Case Rep"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.det.2016.11.006","volume":"35","author":"Harris J.E.","year":"2017","unstructured":"Harris J.E.; Chemical-Induced Vitiligo. Dermatol Clin 2017,35(2),151-161","journal-title":"Dermatol Clin"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"Rodrigues M.","year":"2017","unstructured":"Rodrigues M.; Ezzedine K.; Hamzavi I.; Pandya A.G.; Harris J.E.; New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol Vitiligo Working Group2017,77(1),1-13","journal-title":"J Am Acad Dermatol"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.mayocp.2020.02.012","volume":"95","author":"Shakshouk H","year":"2020","unstructured":"Shakshouk H; Lehman JS; Chemical-associated vitiligo. Mayo Clin Proc 2020,95(6),1105-6","journal-title":"Mayo Clin Proc"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.det.2016.11.005","volume":"35","author":"van Geel N.","year":"2017","unstructured":"van Geel N.; Speeckaert R.; Segmental Vitiligo. Dermatol Clin 2017,35(2),145-150","journal-title":"Dermatol Clin"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40257-019-00430-0","volume":"20","author":"Nicolaidou E.","year":"2019","unstructured":"Nicolaidou E.; Mastraftsi S.; Tzanetakou V.; Rigopoulos D.; Childhood Vitiligo. Am J Clin Dermatol 2019,20(4),515-526","journal-title":"Am J Clin Dermatol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"5617838","DOI":"10.1155\/2017\/5617838","volume":"2017","author":"Vachiramon V.","year":"2017","unstructured":"Vachiramon V.; Onprasert W.; Harnchoowong S.; Chanprapaph K.; Prevalence and clinical characteristics of itch in vitiligo and its clinical significance. BioMed Res Int 2017,2017,5617838","journal-title":"BioMed Res Int"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1468-3083.2010.03694.x","volume":"25","author":"Cho S.B.","year":"2011","unstructured":"Cho S.B.; Kim J.H.; Cho S.; Park J.M.; Park Y.K.; Oh S.H.; Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol 2011,25(1),64-67","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4103\/ijdvl.IJDVL_313_18","volume":"85","author":"Kamat D.","year":"2019","unstructured":"Kamat D.; Prabhakaran N.; Malathi M.; Follicular vitiligo: A rare presentation of vitiligo. Indian J Dermatol Venereol Leprol 2019,85(4),414-415","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.det.2016.11.011","volume":"35","author":"Ta&#xEF;eb A.","year":"2017","unstructured":"Ta&#xEF;eb A.; Seneschal J.; Mazereeuw-Hautier J.; Special Considerations in Children with Vitiligo. Dermatol Clin 2017,35(2),229-233","journal-title":"Dermatol Clin"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.det.2016.11.004","volume":"35","author":"Goh B.K.","year":"2017","unstructured":"Goh B.K.; Pandya A.G.; Presentations, Signs of Activity, and Differential Diagnosis of Vitiligo. Dermatol Clin 2017,35(2),135-144","journal-title":"Dermatol Clin"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1590\/abd1806-4841.20142573","volume":"89","author":"Tarl&#xE9; R.G.","year":"2014","unstructured":"Tarl&#xE9; R.G.; Nascimento L.M.; Mira M.T.; Castro C.C.; Vitiligo--part 1. An Bras Dermatol 2014,89(3),461-470","journal-title":"An Bras Dermatol"},{"key":"ref=77","author":"Manga P","year":"2016","unstructured":"Manga P; Elbuluk N; Orlow SJ; Recent advances in understanding vitiligo. F1000Res 2016","journal-title":"F1000Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3928\/00904481-20090522-01","volume":"38","author":"Isenstein A.L.","year":"2009","unstructured":"Isenstein A.L.; Morrell D.S.; Burkhart C.N.; Vitiligo: treatment approach in children. Pediatr Ann 2009,38(6),339-344","journal-title":"Pediatr Ann"},{"key":"ref=79","first-page":"53","volume":"96","author":"Leung A.K.C.","year":"2017","unstructured":"Leung A.K.C.; Barankin B.; Pigmented lesion with a depigmented rim. Am Fam Physician 2017,96(1),53-54","journal-title":"Am Fam Physician"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/pde.12717","volume":"33","author":"Cohen B.E.","year":"2016","unstructured":"Cohen B.E.; Mu E.W.; Orlow S.J.; Comparison of childhood vitiligo presenting with or without associated halo nevi. Pediatr Dermatol 2016,33(1),44-48","journal-title":"Pediatr Dermatol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/0019-5154.147844","volume":"60","author":"Nagarajan A.","year":"2015","unstructured":"Nagarajan A.; Masthan M.K.; Sankar L.S.; Narayanasamy A.B.; Elumalai R.; Oral manifestations of vitiligo. Indian J Dermatol 2015,60(1),103","journal-title":"Indian J Dermatol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1111\/jdv.15604","volume":"33","author":"van Geel N.","year":"2019","unstructured":"van Geel N.; Grine L.; De Wispelaere P.; Mertens D.; Prinsen C.A.C.; Speeckaert R.; Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019,33(9),1667-1675","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=83","first-page":"125","volume":"15","author":"Ahluwalia J.","year":"2017","unstructured":"Ahluwalia J.; Correa-Selm L.M.; Rao B.K.; Vitiligo: Not simply a skin disease. Skinmed 2017,15(2),125-127","journal-title":"Skinmed"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.det.2016.11.002","volume":"35","author":"Elbuluk N.","year":"2017","unstructured":"Elbuluk N.; Ezzedine K.; Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin 2017,35(2),117-128","journal-title":"Dermatol Clin"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"731","DOI":"10.4103\/idoj.IDOJ_361_18","volume":"10","author":"Prabha N.","year":"2019","unstructured":"Prabha N.; Chhabra N.; Shrivastava A.K.; Arora R.D.; Roja V.R.; Kaushik S.; Nagarkar N.M.; Ocular abnormalities in vitiligo patients: A cross-sectional study. Indian Dermatol Online J 2019,10(6),731-734","journal-title":"Indian Dermatol Online J"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1136\/pgmj.2009.093278","volume":"86","author":"Gawkrodger D.J.","year":"2010","unstructured":"Gawkrodger D.J.; Ormerod A.D.; Shaw L.; Mauri-Sole I.; Whitton M.E.; Watts M.J.; Anstey A.V.; Ingham J.; Young K.; Vitiligo: concise evidence based guidelines on diagnosis and management. Postgrad Med J 2010,86(1018),466-471","journal-title":"Postgrad Med J"},{"key":"ref=87","first-page":"189","volume":"105","author":"Mazzei Weiss M.E.","year":"2020","unstructured":"Mazzei Weiss M.E.; Vitiligo: to biopsy or not to biopsy? Cutis 2020,105(4),189-190","journal-title":"Cutis"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jaad.2017.12.009","volume":"78","author":"Jha A.K.","year":"2018","unstructured":"Jha A.K.; Sonthalia S.; Lallas A.; Dermoscopy as an evolving tool to assess vitiligo activity. J Am Acad Dermatol 2018,78(5),1017-1019","journal-title":"J Am Acad Dermatol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/ijd.13795","volume":"57","author":"Kumar Jha A.","year":"2018","unstructured":"Kumar Jha A.; Sonthalia S.; Lallas A.; Chaudhary R.K.P.; Dermoscopy in vitiligo: diagnosis and beyond. Int J Dermatol 2018,57(1),50-54","journal-title":"Int J Dermatol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"Ezzedine K.","year":"2015","unstructured":"Ezzedine K.; Eleftheriadou V.; Whitton M.; van Geel N.; Vitiligo. Lancet 2015,386(9988),74-84","journal-title":"Lancet"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/2229-5178.96722","volume":"3","author":"Agarwal S.","year":"2012","unstructured":"Agarwal S.; Ojha A.; Piebaldism: A brief report and review of the literature. Indian Dermatol Online J 2012,3(2),144-147","journal-title":"Indian Dermatol Online J"},{"key":"ref=92","first-page":"379","volume":"140","author":"Leung A.K.","year":"1986","unstructured":"Leung A.K.; Feingold M.; Pityriasis alba. Am J Dis Child 1986,140(4),379-380","journal-title":"Am J Dis Child"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.pedhc.2006.05.004","volume":"21","author":"Leung A.K.C.","year":"2007","unstructured":"Leung A.K.C.; Robson W.L.M.; Tuberous sclerosis complex: a review. J Pediatr Health Care 2007,21(2),108-114","journal-title":"J Pediatr Health Care"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.yapd.2007.03.013","volume":"54","author":"Leung A.K.","year":"2007","unstructured":"Leung A.K.; Hon K.L.; Robson W.L.; Atopic dermatitis. Adv Pediatr 2007,54,241-273","journal-title":"Adv Pediatr"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/pch\/pxy009","volume":"23","author":"Leung A.K.C.","year":"2018","unstructured":"Leung A.K.C.; Barankin B.; A linear band of erythematous, flat-topped papules on the forearm. Paediatr Child Health 2018,23(4),260-261","journal-title":"Paediatr Child Health"},{"key":"ref=96","author":"Liu ZH","year":"2020","unstructured":"Liu ZH; Xia XJ; Shen H; Vitiligo-like depigmentation after chromoblastomycosis: a kind of postinflammatory depigmentation due to fungal infection. Mycopathologia 2020","journal-title":"Mycopathologia"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1542\/pir.28-5-193","volume":"28","author":"Qualia C.M.","year":"2007","unstructured":"Qualia C.M.; Brown M.R.; Leung A.K.C.; Robson W.L.M.; Janner D.; Zouros A.; McClure C.; Wycliffe N.; Barron S.; Index of suspicion. Pediatr Rev 2007,28(5),193-198","journal-title":"Pediatr Rev"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/1346-8138.15015","volume":"46","author":"Roh D.","year":"2019","unstructured":"Roh D.; Shin K.; Kim W.I.; Yang M.Y.; Lee W.K.; Kim G.W.; Kim H.S.; Ko H.C.; Kim B.S.; Kim M.B.; Clinical differences between segmental nevus depigmentosus and segmental vitiligo. J Dermatol 2019,46(9),777-781","journal-title":"J Dermatol"},{"key":"ref=99","author":"Roh MR","unstructured":"Roh MR; Acquired hypopigmentation disorders other than vitiligo. UpToDate","journal-title":"UpToDate"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.16049","volume":"178","author":"Osinubi O.","year":"2018","unstructured":"Osinubi O.; Grainge M.J.; Hong L.; Ahmed A.; Batchelor J.M.; Grindlay D.; Thompson A.R.; Ratib S.; The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol 2018,178(4),863-878","journal-title":"Br J Dermatol"},{"key":"ref=101","first-page":"688","volume":"17","author":"Rzepecki A.K.","year":"2018","unstructured":"Rzepecki A.K.; McLellan B.N.; Elbuluk N.; Beyond traditional treatment: The importance of psychosocial therapy in vitiligo. J Drugs Dermatol 2018,17(6),688-691","journal-title":"J Drugs Dermatol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/pde.12226","volume":"31","author":"Silverberg J.I.","year":"2014","unstructured":"Silverberg J.I.; Silverberg N.B.; Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol 2014,31(3),309-318","journal-title":"Pediatr Dermatol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"e13418","DOI":"10.1111\/dth.13418","volume":"33","author":"Simons R.E.","year":"2020","unstructured":"Simons R.E.; Zevy D.L.; Jafferany M.; Psychodermatology of vitiligo: Psychological impact and consequences. Dermatol Ther (Heidelb) 2020,33(3),e13418","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=104","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14196","author":"Ucuz I","year":"2020","unstructured":"Ucuz I; Altunisik N; Sener S; Turkmen D; Kavuran NA; Marsak M; Quality of life, emotion dysregulation, attention deficit and psychiatric comorbidity in children and adolescents with vitiligo. Clin Exp Dermatol 2020","journal-title":"Clin Exp Dermatol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.clindermatol.2014.02.006","volume":"32","author":"Silverberg N.B.","year":"2014","unstructured":"Silverberg N.B.; Recent advances in childhood vitiligo. Clin Dermatol 2014,32(4),524-530","journal-title":"Clin Dermatol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/CCID.S151114","volume":"11","author":"Bidaki R.","year":"2018","unstructured":"Bidaki R.; Majidi N.; Moghadam Ahmadi A.; Bakhshi H.; Sadr Mohammadi R.; Mostafavi S.A.; Kazemi Arababadi M.; Hadavi M.; Mirzaei A.; Vitiligo and social acceptance. Clin Cosmet Investig Dermatol 2018,11,383-386","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/bjd.16072","volume":"178","author":"Ezzedine K.","year":"2018","unstructured":"Ezzedine K.; Eleftheriadou V.; Vitiligo and quality of life: the dark face of whiteness. Br J Dermatol 2018,178(1),28-29","journal-title":"Br J Dermatol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ad.2017.03.007","volume":"108","author":"Morales-S&#xE1;nchez M.A.","year":"2017","unstructured":"Morales-S&#xE1;nchez M.A.; Vargas-Salinas M.; Peralta-Pedrero M.L.; Olgu&#xED;n-Garc&#xED;a M.G.; Jurado-Santa Cruz F.; Impacto del vit&#xED;ligo en la calidad de vida. Actas Dermosifiliogr 2017,108(7),637-642","journal-title":"Actas Dermosifiliogr"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/bjd.15933","volume":"177","author":"Morrison B.","year":"2017","unstructured":"Morrison B.; Burden-Teh E.; Batchelor J.M.; Mead E.; Grindlay D.; Ratib S.; Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol 2017,177(6),e338-e339","journal-title":"Br J Dermatol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1111\/dth.12007","volume":"25","author":"Teovska Mitrevska N.","year":"2012","unstructured":"Teovska Mitrevska N.; Eleftheriadou V.; Guarneri F.; Quality of life in vitiligo patients. Dermatol Ther (Heidelb) 2012,25(Suppl. 1),S28-S31","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s41687-020-0186-2","volume":"4","author":"Andrade G.","year":"2020","unstructured":"Andrade G.; Rangu S.; Provini L.; Putterman E.; Gauthier A.; Castelo-Soccio L.; Childhood vitiligo impacts emotional health of parents: a prospective, cross-sectional study of quality of life for primary caregivers. J Patient Rep Outcomes 2020,4(1),20","journal-title":"J Patient Rep Outcomes"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/jdv.12169","volume":"28","author":"van Geel N.","year":"2014","unstructured":"van Geel N.; Speeckaert M.; Brochez L.; Lambert J.; Speeckaert R.; Clinical profile of generalized vitiligo patients with associated autoimmune\/autoinflammatory diseases. J Eur Acad Dermatol Venereol 2014,28(6),741-746","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000081479","volume":"210","author":"Iacovelli P.","year":"2005","unstructured":"Iacovelli P.; Sinagra J.L.M.; Vidolin A.P.; Marenda S.; Capitanio B.; Leone G.; Picardo M.; Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology 2005,210(1),26-30","journal-title":"Dermatology"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jocd.12022","volume":"12","author":"Anbar T.","year":"2013","unstructured":"Anbar T.; Hay R.A.; Abdel-Rahman A.T.; Moftah N.H.; Al-Khayyat M.A.; Clinical study of nail changes in vitiligo. J Cosmet Dermatol 2013,12(1),67-72","journal-title":"J Cosmet Dermatol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1590\/abd1806-4841.20164620","volume":"91","author":"Topal I.O.","year":"2016","unstructured":"Topal I.O.; Gungor S.; Kocaturk O.E.; Duman H.; Durmuscan M.; Nail abnormalities in patients with vitiligo. An Bras Dermatol [F].2016,91(4),442-445","journal-title":"An Bras Dermatol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/ijd.13031","volume":"55","author":"Karadag R.","year":"2016","unstructured":"Karadag R.; Esmer O.; Karadag A.S.; Bilgili S.G.; Cakici O.; Demircan Y.T.; Bayramlar H.; Evaluation of ocular findings in patients with vitiligo. Int J Dermatol 2016,55(3),351-355","journal-title":"Int J Dermatol"},{"key":"ref=117","first-page":"109","volume":"14","author":"Sarnoff D.S.","year":"2015","unstructured":"Sarnoff D.S.; Therapeutic update on vitiligo. J Drugs Dermatol 2015,14(2),109-111","journal-title":"J Drugs Dermatol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1346-8138.2009.00774.x","volume":"37","author":"Lo Y.H.","year":"2010","unstructured":"Lo Y.H.; Cheng G.S.; Huang C.C.; Chang W.Y.; Wu C.S.; Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo. J Dermatol 2010,37(2),125-129","journal-title":"J Dermatol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1517\/14656566.2012.712113","volume":"13","author":"Colucci R.","year":"2012","unstructured":"Colucci R.; Lotti T.; Moretti S.; Vitiligo: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 2012,13(13),1885-1899","journal-title":"Expert Opin Pharmacother"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4103\/ijdvl.IJDVL_409_18","volume":"86","author":"Taneja N.","year":"2020","unstructured":"Taneja N.; Sreenivas V.; Sahni K.; Gupta V.; Ramam M.; A cross-sectional study of spontaneous repigmentation in vitiligo. Indian J Dermatol Venereol Leprol 2020,86(3),240-250","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaad.2015.05.038","volume":"73","author":"Mu E.W.","year":"2015","unstructured":"Mu E.W.; Cohen B.E.; Orlow S.J.; Early-onset childhood vitiligo is associated with a more extensive and progressive course. J Am Acad Dermatol 2015,73(3),467-470","journal-title":"J Am Acad Dermatol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00432-020-03245-3","volume":"146","author":"Wen Y.","year":"2020","unstructured":"Wen Y.; Wu X.; Peng H.; Li C.; Jiang Y.; Liang H.; Zhong R.; Liu J.; He J.; Liang W.; Cancer risks in patients with vitiligo: a Mendelian randomization study. J Cancer Res Clin Oncol 2020,146(8),1933-1940","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1525-1470.2010.01159.x","volume":"27","author":"Tamesis M.E.","year":"2010","unstructured":"Tamesis M.E.; Morelli J.G.; Vitiligo treatment in childhood: a state of the art review. Pediatr Dermatol 2010,27(5),437-445","journal-title":"Pediatr Dermatol"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/jocd.13459","volume":"20","author":"Bassiouny D","year":"2020","unstructured":"Bassiouny D; Hegazy R; Esmat S; Gawdat HI; Ahmed Ezzat M; Tawfik HA; Cosmetic camouflage as an adjuvant to vitiligo therapies: Effect on quality of life. J Cosmet Dermatol 2020,20(1),159-65","journal-title":"J Cosmet Dermatol"},{"key":"ref=125","first-page":"384","volume":"15","author":"Hossain C.","year":"2016","unstructured":"Hossain C.; Porto D.A.; Hamzavi I.; Lim H.W.; Camouflaging agents for vitiligo patients. J Drugs Dermatol 2016,15(4),384-387","journal-title":"J Drugs Dermatol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14728214.2020.1712358","volume":"25","author":"Karagaiah P.","year":"2020","unstructured":"Karagaiah P.; Valle Y.; Sigova J.; Zerbinati N.; Vojvodic P.; Parsad D.; Schwartz R.A.; Grabbe S.; Goldust M.; Lotti T.; Emerging drugs for the treatment of vitiligo. Expert Opin Emerg Drugs 2020,25(1),7-24","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jaad.2010.10.043","volume":"65","author":"Felsten L.M.","year":"2011","unstructured":"Felsten L.M.; Alikhan A.; Petronic-Rosic V.; Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment. J Am Acad Dermatol 2011,65(3),493-514","journal-title":"J Am Acad Dermatol"},{"key":"ref=128","author":"Grimes PE","unstructured":"Grimes PE; Vitiligo: Management and prognosis. UpToDate Waltham, MA","journal-title":"UpToDate Waltham, MA"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40272-015-0135-3","volume":"17","author":"Van Driessche F.","year":"2015","unstructured":"Van Driessche F.; Silverberg N.; Current management of pediatric vitiligo. Paediatr Drugs 2015,17(4),303-313","journal-title":"Paediatr Drugs"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","volume":"77","author":"Rodrigues M.","year":"2017","unstructured":"Rodrigues M.; Ezzedine K.; Hamzavi I.; Pandya A.G.; Harris J.E.; Current and emerging treatments for vitiligo. J Am Acad Dermatol Vitiligo Working Group2017,77(1),17-29","journal-title":"J Am Acad Dermatol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1111\/j.1529-8019.2008.00198.x","volume":"21","author":"Lotti T.","year":"2008","unstructured":"Lotti T.; Buggiani G.; Troiano M.; Assad G.B.; Delescluse J.; De Giorgi V.; Hercogova J.; Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther 2008,21(Suppl. 1),S20-S26","journal-title":"Dermatol Ther"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"e13215","DOI":"10.1111\/dth.13215","volume":"33","author":"Agarwal K.","year":"2020","unstructured":"Agarwal K.; Podder I.; Kassir M.; Vojvodic A.; Schwartz R.A.; Wollina U.; Valle Y.; Lotti T.; Rokni G.R.; Grabbe S.; Goldust M.; Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature. Dermatol Ther (Heidelb) 2020,33(2),e13215","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3889\/oamjms.2018.054","volume":"6","author":"Gianfaldoni S.","year":"2018","unstructured":"Gianfaldoni S.; Wollina U.; Tchernev G.; Lotti J.; Fran&#xE7;a K.; Lotti T.; Vitiligo in children: A review of conventional treatments. Open Access Maced J Med Sci 2018,6(1),213-217","journal-title":"Open Access Maced J Med Sci"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/17460441.2020.1722639","volume":"15","author":"Hon K.L.","year":"2020","unstructured":"Hon K.L.; Loo S.; Leung A.K.C.; Li J.T.S.; Lee V.W.Y.; An overview of drug discovery efforts for eczema: why is this itch so difficult to scratch? Expert Opin Drug Discov 2020,15(4),487-498","journal-title":"Expert Opin Drug Discov"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/14740338.2020.1729737","volume":"19","author":"Lotti T.","year":"2020","unstructured":"Lotti T.; Agarwal K.; Podder I.; Satolli F.; Kassir M.; Schwartz R.A.; Wollina U.; Grabbe S.; Navarini A.A.; Mueller S.M.; Goldust M.; Safety of the current drug treatments for vitiligo. Expert Opin Drug Saf 2020,19(4),499-511","journal-title":"Expert Opin Drug Saf"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/13543784.2018.1494723","volume":"27","author":"Hon K.L.","year":"2018","unstructured":"Hon K.L.; Leung A.K.C.; Leung T.N.H.; Lee V.W.Y.; Investigational drugs for atopic dermatitis. Expert Opin Investig Drugs 2018,27(8),637-647","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","volume":"155","author":"Lee J.H.","year":"2019","unstructured":"Lee J.H.; Kwon H.S.; Jung H.M.; Lee H.; Kim G.M.; Yim H.W.; Bae J.M.; Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: A systematic review and meta-analysis. JAMA Dermatol 2019,155(8),929-938","journal-title":"JAMA Dermatol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaad.2019.07.108","volume":"82","author":"Chang H.C.","year":"2020","unstructured":"Chang H.C.; Hsu Y.P.; Huang Y.C.; The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: A systematic review and meta-analysis. J Am Acad Dermatol 2020,82(1),243-245","journal-title":"J Am Acad Dermatol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1365-2133.2011.10351.x","volume":"165","author":"Ho N.","year":"2011","unstructured":"Ho N.; Pope E.; Weinstein M.; Greenberg S.; Webster C.; Krafchik B.R.; A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0&#xB7;1% vs. clobetasol propionate 0&#xB7;05% in childhood vitiligo. Br J Dermatol 2011,165(3),626-632","journal-title":"Br J Dermatol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/archderm.139.5.581","volume":"139","author":"Lepe V.","year":"2003","unstructured":"Lepe V.; Moncada B.; Castanedo-Cazares J.P.; Torres-Alvarez M.B.; Ortiz C.A.; Torres-Rubalcava A.B.; A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003,139(5),581-585","journal-title":"Arch Dermatol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/ddg.13680","volume":"16","author":"Bleuel R.","year":"2018","unstructured":"Bleuel R.; Eberlein B.; Therapeutic management of vitiligo. J Dtsch Dermatol Ges 2018,16(11),1309-1313","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref=142","first-page":"1","volume":"24","author":"Nahhas A.F.","year":"2019","unstructured":"Nahhas A.F.; Braunberger T.L.; Hamzavi I.H.; Update on the management of vitiligo. Skin Therapy Lett 2019,24(3),1-6","journal-title":"Skin Therapy Lett"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/bjd.18890","volume":"183","author":"Parihar A.S.","year":"2020","unstructured":"Parihar A.S.; Tembhre M.K.; Sharma V.K.; Gupta S.; Chattopadhyay P.; Deepak K.K.; Effect of narrowband ultraviolet B treatment on microRNA expression in active nonsegmental generalized vitiligo. Br J Dermatol 2020,183(1),167-169","journal-title":"Br J Dermatol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1525-1470.2011.01683.x","volume":"29","author":"Percivalle S.","year":"2012","unstructured":"Percivalle S.; Piccinno R.; Caccialanza M.; Forti S.; Narrowband ultraviolet B phototherapy in childhood vitiligo: evaluation of results in 28 patients. Pediatr Dermatol 2012,29(2),160-165","journal-title":"Pediatr Dermatol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.det.2019.08.005","volume":"38","author":"Zubair R.","year":"2020","unstructured":"Zubair R.; Hamzavi I.H.; Phototherapy for Vitiligo. Dermatol Clin 2020,38(1),55-62","journal-title":"Dermatol Clin"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","volume":"153","author":"Bae J.M.","year":"2017","unstructured":"Bae J.M.; Jung H.M.; Hong B.Y.; Lee J.H.; Choi W.J.; Lee J.H.; Kim G.M.; Phototherapy for vitiligo: A systematic review and meta-analysis. JAMA Dermatol 2017,153(7),666-674","journal-title":"JAMA Dermatol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3109\/09546634.2014.952610","volume":"26","author":"Xiao B.H.","year":"2015","unstructured":"Xiao B.H.; Wu Y.; Sun Y.; Chen H.D.; Gao X.H.; Treatment of vitiligo with NB-UVB: A systematic review. J Dermatolog Treat 2015,26(4),340-346","journal-title":"J Dermatolog Treat"},{"key":"ref=148","first-page":"15","volume":"10","author":"Dillon AB","year":"2017","unstructured":"Dillon AB; Sideris A; Hadi A; Elbuluk N; Advances in Vitiligo: An Update on Medical and Surgical Treatments. J Clin Aesthet Dermatol 2017,10(1),15-28","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00403-020-02068-z","volume":"313","author":"Gauthier Y","year":"2021","unstructured":"Gauthier Y; Almasi-Nasrabadi M; Cario-Andr&#xE9; M; Pain C; Rakhshan A; Ghalamkarpour F; Tacrolimus (FK506) ointment combined with Nb-UVB could activate both hair follicle (HF) and dermal melanocyte precursors in vitiligo: the first histopathological and clinical study. Arch Dermatol Res 2021,313(5),383-8","journal-title":"Arch Dermatol Res"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3889\/oamjms.2018.060","volume":"6","author":"Gianfaldoni S.","year":"2018","unstructured":"Gianfaldoni S.; Tchernev G.; Wollina U.; Lotti J.; Rovesti M.; Satolli F.; Fran&#xE7;a K.; Lotti T.; Vitiligo in children: What\u2019s new in treatment? Open Access Maced J Med Sci 2018,6(1),221-225","journal-title":"Open Access Maced J Med Sci"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10103-020-03069-0","volume":"36","author":"Kim WI","year":"2020","unstructured":"Kim WI; Kim S; Lee SH; Cho MK; The efficacy of fractional carbon dioxide laser combined with narrow-band ultraviolet B phototherapy for non-segmental vitiligo: a systematic review and meta-analysis. Lasers Med Sci 2020,36(1),165-73","journal-title":"Lasers Med Sci"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2165\/11630540-000000000-00000","volume":"13","author":"Bacigalupi R.M.","year":"2012","unstructured":"Bacigalupi R.M.; Postolova A.; Davis R.S.; Evidence-based, non-surgical treatments for vitiligo: a review. Am J Clin Dermatol 2012,13(4),217-237","journal-title":"Am J Clin Dermatol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3346\/jkms.2005.20.2.273","volume":"20","author":"Hong S.B.","year":"2005","unstructured":"Hong S.B.; Park H.H.; Lee M.H.; Short-term effects of 308-nm xenon-chloride excimer laser and narrow-band ultraviolet B in the treatment of vitiligo: a comparative study. J Korean Med Sci 2005,20(2),273-278","journal-title":"J Korean Med Sci"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1365-2133.2010.09778.x","volume":"163","author":"Le Duff F.","year":"2010","unstructured":"Le Duff F.; Fontas E.; Giacchero D.; Sillard L.; Lacour J.P.; Ortonne J.P.; Passeron T.; 308-nm excimer lamp vs. 308-nm excimer laser for treating vitiligo: a randomized study. Br J Dermatol 2010,163(1),188-192","journal-title":"Br J Dermatol"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"e13408","DOI":"10.1111\/dth.13408","volume":"33","author":"Majid I.","year":"2020","unstructured":"Majid I.; Imran S.; Excimer light therapy in childhood segmental vitiligo: Early treatment gives better results. Dermatol Ther (Heidelb) 2020,33(3),e13408","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s10103-020-03048-5","volume":"35","author":"Juntongjin P","year":"2020","unstructured":"Juntongjin P; Toncharoenphong N; Effectiveness of a combined 308-nm excimer lamp and topical mid-potent steroid treatment for facial vitiligo: a preliminary, randomized double-blinded controlled study. Lasers Med Sci 2020,35,2023-9","journal-title":"Lasers Med Sci"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/bjd.18101","volume":"181","author":"Silpa-Archa N","year":"2019","unstructured":"Silpa-Archa N; Lim HW; Wongpraparut C; Excimer laser in vitiligo: where there is light, there is hope. Br J Dermatol 2019,181(1),21-2","journal-title":"Br J Dermatol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2016.12399","volume":"316","author":"Ezzedine K.","year":"2016","unstructured":"Ezzedine K.; Whitton M.; Pinart M.; Interventions for Vitiligo. JAMA 2016,316(16),1708-1709","journal-title":"JAMA"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/ijd.14924","volume":"59","author":"Dalla A.","year":"2020","unstructured":"Dalla A.; Parsad D.; Vinay K.; Thakur V.; Sendhil Kumaran M.; A prospective study to assess the efficacy of various surgical modalities in treatment of stable vitiligo patches over resistant sites. Int J Dermatol 2020,59(7),837-842","journal-title":"Int J Dermatol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/039463201402700403","volume":"27","author":"Ghafourian A.","year":"2014","unstructured":"Ghafourian A.; Ghafourian S.; Sadeghifard N.; Mohebi R.; Shokoohini Y.; Nezamoleslami S.; Hamat R.A.; Vitiligo: symptoms, pathogenesis and treatment. Int J Immunopathol Pharmacol 2014,27(4),485-489","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref=161","first-page":"705","volume":"16","author":"Garza-Mayers A.C.","year":"2017","unstructured":"Garza-Mayers A.C.; Kroshinsky D.; Low-dose methotrexate for vitiligo. J Drugs Dermatol 2017,16(7),705-706","journal-title":"J Drugs Dermatol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2147\/CCID.S229175","volume":"12","author":"Konstantinova V.A.","year":"2019","unstructured":"Konstantinova V.A.; Olisova O.Y.; Gladko V.V.; Burova E.P.; Vitiligo - New treatment approach. Clin Cosmet Investig Dermatol 2019,12,911-917","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ajd.12256","volume":"56","author":"Daniel B.S.","year":"2015","unstructured":"Daniel B.S.; Wittal R.; Vitiligo treatment update. Australas J Dermatol 2015,56(2),85-92","journal-title":"Australas J Dermatol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2147\/DDDT.S239912","volume":"14","author":"Mercuri S.R.","year":"2020","unstructured":"Mercuri S.R.; Vollono L.; Paolino G.; The usefulness of platelet-rich plasma (PRP) for the treatment of vitiligo: State of the art and review. Drug Des Devel Ther 2020,14,1749-1755","journal-title":"Drug Des Devel Ther"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"e13175","DOI":"10.1111\/dth.13175","volume":"33","author":"Nowroozpoor Dailami K.","year":"2020","unstructured":"Nowroozpoor Dailami K.; Hosseini A.; Rahmatpour Rokni G.; Saeedi M.; Morteza-Semnani K.; Sadeghi Z.; Ghasemzadeh Diva S.M.; Goldust M.; Lotti T.; Vojvodic A.; Goren A.; Sonthalia S.; Rathod D.; Efficacy of topical latanoprost in the treatment of eyelid vitiligo: A randomized, double-blind clinical trial study. Dermatol Ther (Heidelb) 2020,33(1),e13175","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/ijd.12631","volume":"54","author":"Anbar T.S.","year":"2015","unstructured":"Anbar T.S.; El-Ammawi T.S.; Abdel-Rahman A.T.; Hanna M.R.; The effect of latanoprost on vitiligo: a preliminary comparative study. Int J Dermatol 2015,54(5),587-593","journal-title":"Int J Dermatol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/cei.12168","volume":"174","author":"Ruiz-Arg&#xFC;elles A.","year":"2013","unstructured":"Ruiz-Arg&#xFC;elles A.; Garc&#xED;a-Carrasco M.; Jimenez-Brito G.; S&#xE1;nchez-Sosa S.; P&#xE9;rez-Romano B.; Garc&#xE9;s-Eisele J.; Camacho-Alarc&#xF3;n C.; Reyes-N&#xFA;&#xF1;ez V.; Sandoval-Cruz M.; Mendoza-Pinto C.; L&#xF3;pez-Colombo A.; Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol 2013,174(2),229-236","journal-title":"Clin Exp Immunol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1203475419833609","volume":"23","author":"Relke N.","year":"2019","unstructured":"Relke N.; Gooderham M.; The use of Janus kinase inhibitors in vitiligo: A review of the literature. J Cutan Med Surg [R].2019,23(3),298-306","journal-title":"J Cutan Med Surg"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"Craiglow B.G.","year":"2015","unstructured":"Craiglow B.G.; King B.A.; Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy. JAMA Dermatol 2015,151(10),1110-1112","journal-title":"JAMA Dermatol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/ajd.13348","volume":"61","author":"Mumford BP","year":"2020","unstructured":"Mumford BP; Gibson A; Chong AH; Repigmentation of vitiligo with oral baricitinib. Australas J Dermatol 2020,61(4),374-6","journal-title":"Australas J Dermatol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/pde.14159","volume":"37","author":"Olamiju B","year":"2020","unstructured":"Olamiju B; Craiglow BG; Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child. Pediatr Dermatol 2020,37(4),754-5","journal-title":"Pediatr Dermatol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","volume":"81","author":"McKesey J.","year":"2019","unstructured":"McKesey J.; Pandya A.G.; A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo. J Am Acad Dermatol 2019,81(2),646-648","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Pediatric Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573396316666201210125858","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188993\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573396316666201210125858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T19:37:30Z","timestamp":1660419450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188993\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":172,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573396316666201210125858","relation":{},"ISSN":["1573-3963"],"issn-type":[{"value":"1573-3963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}